Fermentalg: Revenue Up 16% in 2025, Reaching €13.4 Million
Fermentalg continued its growth in 2025 with a revenue of €13.4 million, marking a 16% increase despite an unfavorable context characterized by geopolitical tensions, a drop in fish oil prices, the weakening of the dollar against the euro, and increased tariffs in the American and Chinese markets. The group highlights the evolution of its commercial positioning, shifting from a raw material sales strategy to a finished product and concept sales approach. In 2026, Fermentalg aims to accelerate its growth and realize the development of new innovative biosolutions.
Real Commercial Growth Driven by Processed Products
Fermentalg's revenue stood at €13.4 million in 2025, up 16% from the previous year. This growth occurred in an unfavorable environment, marked by the drop in fish oil prices from $9 to $3 per kilogram, the weakening of the dollar against the euro, and increased tariffs in the American and Chinese markets. Commercially, Fermentalg has evolved its positioning from a raw material sales logic to an approach based on finished products and concept sales.
Omega-3, Infant Nutrition, and Aquaculture Support Activity
Sales in the infant nutrition and aquaculture segments accounted for over 40% of the revenues in 2025. Industrially, the complete transfer of Omega-3 production to the partner HuvePharma resulted in a 40% productivity gain. The opening of a refining unit also strengthened control over the production chain for applications developed by Fermentalg, particularly around the ΩRIGINS range for Omega-3 and Galdieria Blue for natural coloring.
Regulatory Approvals and Organizational Structure Enhance Market Presence
In May 2025, Fermentalg received authorization from the Food and Drug Administration to market its natural blue colorant Galdieria Blue in the United States. In Europe, the European Food Safety Authority issued a favorable opinion in March 2026. These advancements should enable the company to continue the commercial development of Galdieria Blue, in collaboration with HuvePharma for industrial production and Givaudan for marketing in food applications. Fermentalg has structured its organization around two value-creating poles in 2025. The operations pole aims to satisfy and acquire new customers, coordinating purchases, planning, customer service, quality, industrial optimization, sales, and marketing. The new biosolutions design pole brings together 30 experts involved in various stages of development, from product to market launch. In 2026, Fermentalg intends to capitalize on its experiences and investments to accelerate growth and realize the development of new innovative biosolutions. The group mentions the launch of Galdieria Blue, the development of the Kalvea range dedicated to algal proteins for animal nutrition, and the exploration of new biosolutions. Fermentalg affirms it is entering this new phase with a business model described as 'fair, differentiating, and carrying sustainable value' for its stakeholders.
